Department of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China.
Henan Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang Medical University, Xinxiang, 453003, China.
Sci Rep. 2018 Apr 24;8(1):6435. doi: 10.1038/s41598-018-24879-x.
Helicobacter pylori neutrophil-activating protein A subunit (NapA) has been identified as a virulence factor, a protective antigen and a potent immunomodulator. NapA shows unique application potentials for anti-H. pylori vaccines and treatment strategies of certain allergic diseases and carcinomas. However, appropriate production and utilization modes of NapA still remain uncertain to date. This work has established a novel efficient production and utilization mode of NapA by using L. lactis as an expression host and delivery vector, and demonstrated immune protective efficacy and immune modulatory activity of the engineered L. lactis by oral vaccination of mice. It was observed for the first time that H. pylori NapA promotes both polarized Th17 and Th1 responses, which may greatly affect the clinical application of NapA. This report offers a promising anti-H. pylori oral vaccine candidate and a potent mucosal immune modulatory agent. Meanwhile, it uncovers a way to produce and deliver the oral vaccine and immunomodulator by fermentation of food like milk, which might have striking effects on control of H. pylori infection, gastrointestinal cancers, and Th2 bias allergic diseases, including many food allergies.
幽门螺杆菌中性粒细胞激活蛋白 A 亚单位（NapA）已被鉴定为一种毒力因子、保护性抗原和有效的免疫调节剂。NapA 在抗幽门螺杆菌疫苗的开发以及某些过敏性疾病和癌的治疗策略方面具有独特的应用潜力。然而，NapA 的适宜生产和利用模式至今仍不确定。本研究利用乳球菌作为表达宿主和载体，建立了一种新型的、高效的 NapA 生产和利用模式，并通过小鼠口服免疫接种，证实了工程化乳球菌的免疫保护效果和免疫调节活性。本研究首次观察到幽门螺杆菌 NapA 可促进极化的 Th17 和 Th1 反应，这可能会极大地影响 NapA 的临床应用。本报告为抗幽门螺杆菌口服疫苗候选物和有效的黏膜免疫调节剂提供了新的思路。同时，该研究揭示了一种通过发酵牛奶等食品来生产和递送口服疫苗和免疫调节剂的方法，这可能对控制幽门螺杆菌感染、胃肠道癌和 Th2 偏向性过敏疾病（包括许多食物过敏）产生显著影响。
